Cystic fibrosis (CF) is a common genetic disorders that has been well studied. Researchers have identified CF-causing mutations in a gene called CFTR, which encodes for an ion channel. The genetic ...
Please provide your email address to receive an email when new articles are posted on . Few patients with cystic fibrosis have a copy of the 3849+10kb C-to-T splicing mutation. Research is planned to ...
Please provide your email address to receive an email when new articles are posted on . The Cystic Fibrosis Foundation is providing funds to Prime Medicine to advance research on its gene editing ...
- ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head ...
Genetic testing can help determine if you carry a gene mutation responsible for cystic fibrosis. It may be done using blood, saliva, or cheek tissue samples. The American Lung Association estimates ...
Maren Denison, third-year student at the University of Iowa, was in sixth grade when she found out her lung function had dropped to 60 percent as half of her lung had collapsed and was scarred shut.
The FDA approved a once-daily oral combination of vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis (CF) in adults and children 6 years and up ...
Hosted on MSN
Gene therapy targets untreatable cystic fibrosis mutation affecting about 10% of patients
Cystic fibrosis is among the most common, known and studied genetic diseases. It affects over 100,000 people worldwide and reduces life expectancy mainly as it causes lung and respiratory problems.
An optimized version of prime editing technology raises the possibility of a one-time treatment for cystic fibrosis. In their 2019 paper, Liu’s team used prime editing to alter the gene mutations ...
If you and your partner both are carriers for CF, it doesn’t necessarily mean your child will have CF. But it will likely still affect your pregnancy. Genetic disorders range widely from long-term yet ...
A nanobody that stabilizes mutant CFTR from inside the cell, especially when combined with existing drugs, restores near-normal function in cystic fibrosis cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results